Yu Joshua Cao
Affiliations: | 2013-2016 | Chemistry | Scripps Research Institute, La Jolla, La Jolla, CA, United States |
| 2017- | Chemical Biology and Biotechnology | Peking University Shenzhen Graduate School |
Google:
"Yu Cao"Parents
Sign in to add mentor| Gang Bai | grad student | 2001-2007 | Nankai University |
| Michael G. Rosenblum | grad student | 2007-2013 | University of Texas, MD Anderson Cancer Center |
| Peter G. Schultz | post-doc | 2013-2016 | Scripps Institute |
Children
Sign in to add trainee| Zhidong Wang | grad student | 2018-2022 | Peking University |
| Lijun Zhao | grad student | 2018-2022 | Peking University |
| Shuhong Li | grad student | 2019-2023 | Peking University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li S, Shi L, Zhao L, et al. (2024) Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies. Nature Communications. 15: 9751 |
| Xi R, Cao Y, Fu N, et al. (2024) Allosteric inhibition of the tyrosine phosphatase SHP2 enhances the anti-tumor immunity of interferon α through induction of caspase-1-mediated pyroptosis in renal cancer. International Immunopharmacology. 143: 113498 |
| Zhou X, Chen Z, Yu Y, et al. (2024) Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8 T Cell Activation and Allow Tumor Immune Escape. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2403629 |
| Geva R, Vieito M, Ramon J, et al. (2024) Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. Cancer Immunology, Immunotherapy : Cii. 73: 205 |
| Zhao L, Li S, Wei X, et al. (2024) A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances. Protein & Cell |
| Yin N, Li X, Zhang X, et al. (2024) Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduction and Targeted Therapy. 9: 126 |
| Mandula JK, Sierra-Mondragon RA, Jimenez RV, et al. (2024) Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. Immunity |
| Hu R, Cao Y, Wang Y, et al. (2024) TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. Breast Cancer Research : Bcr. 26: 48 |
| He M, Zhang D, Cao Y, et al. (2023) Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. Heliyon. 9: e19147 |
| Cao Y, Efetov SK, He M, et al. (2023) Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Archivum Immunologiae Et Therapiae Experimentalis. 71: 19 |